Cargando…

Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL

BACKGROUND: The study objectives were to assess the prognostic value of quantitative PET and to test whether combining baseline metabolic tumour burden with early PET response could improve predictive power in DLBCL. METHODS: A total of 147 patients with DLBCL underwent FDG-PET/CT scans before and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mikhaeel, N. George, Smith, Daniel, Dunn, Joel T., Phillips, Michael, Møller, Henrik, Fields, Paul A., Wrench, David, Barrington, Sally F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865540/ https://www.ncbi.nlm.nih.gov/pubmed/26902371 http://dx.doi.org/10.1007/s00259-016-3315-7

Ejemplares similares

Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma
por: Ilyas, Hajira, et al.
Publicado: (2018)

Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
por: Jemaa, S., et al.
Publicado: (2022)

New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT
por: Cottereau, Anne-Ségolène, et al.
Publicado: (2021)

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas
por: Barrington, Sally F., et al.
Publicado: (2016)

Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL
por: Zhao, Peng, et al.
Publicado: (2020)

Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim (18)FDG PET/CT Using Standardized Imaging and Reporting Protocols
por: Zaman, Maseeh uz, et al.
Publicado: (2020)

Primary Isolated Lymphoplasmacytic Lymphoma (LPL) of the Stomach: A Case Report
por: Attallah, Hany S., et al.
Publicado: (2020)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

A case–control evaluation of pulmonary and extrapulmonary findings of incidental asymptomatic COVID-19 infection on FDG PET-CT
por: Subesinghe, Manil, et al.
Publicado: (2022)

Prognostic value of baseline total metabolic tumour volume of (18)F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma
por: Gong, Huanyu, et al.
Publicado: (2021)

Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand
por: Boellaard, Ronald, et al.
Publicado: (2019)

Prognostic Impact of Pretreatment 2-[(18)F]-FDG PET/CT Parameters in Primary Gastric DLBCL
por: Albano, Domenico, et al.
Publicado: (2021)

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.
por: Martinez, Celia, et al.
Publicado: (2023)

Test-retest Repeatability and Interobserver Variation of Healthy Tissue Metabolism using FDG-PET/CT of the Thorax among Lung Cancer Patients
por: Malaih, Afnan A., et al.
Publicado: (2022)

Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer
por: Lai, Alta Y. T., et al.
Publicado: (2017)

Healthy Organs Uptake on Baseline (18)F-FDG PET/CT as an Alternative to Total Metabolic Tumor Volume to Predict Event-Free Survival in Classical Hodgkin's Lymphoma
por: Morland, David, et al.
Publicado: (2022)

Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
por: Eertink, J. J., et al.
Publicado: (2023)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
por: Boellaard, Ronald, et al.
Publicado: (2014)

Interim and end‐of‐treatment PET‐CT suffers from high false‐positive rates in DLBCL: Biopsy is needed prior to treatment decisions
por: Tokola, Susanna, et al.
Publicado: (2021)

Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
por: Kolinger, Guilherme D., et al.
Publicado: (2019)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

Comparing approaches to correct for respiratory motion in NH(3) PET-CT cardiac perfusion imaging
por: Schleyer, Paul J., et al.
Publicado: (2013)

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
por: Eertink, J. J., et al.
Publicado: (2021)

Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging
por: Boellaard, Ronald, et al.
Publicado: (2010)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

Congruency of tumour volume delineated by FET PET and MRSI
por: Mauler, Jörg, et al.
Publicado: (2015)

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
por: Nygaard, A D, et al.
Publicado: (2014)

When SUV Matters: FDG PET/CT at Baseline Correlates with Survival in Soft Tissue and Ewing Sarcoma
por: Hack, Ruben I., et al.
Publicado: (2021)

PET/CT in oncology: for which tumours is it the reference standard?
por: Collins, Conor D.
Publicado: (2007)

The role of PET-CT in radiotherapy planning of solid tumours
por: Jelercic, Stasa, et al.
Publicado: (2015)

Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era
por: Jelicic, Jelena, et al.
Publicado: (2023)

Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
por: Ritter, Zsombor, et al.
Publicado: (2022)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
por: Mazzara, Saveria, et al.
Publicado: (2022)

Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
por: Pinochet, Pierre, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mi0dlfikbsom5d284kvq0ivkn8